| Literature DB >> 35329054 |
Mateusz Lucki1, Ewa Chlebuś1, Agnieszka Wareńczak1, Przemysław Daroszewski2, Przemysław Lisiński1.
Abstract
BACKGROUND: Patients after undergoing ischemic stroke have a high risk of further cardiovascular disease (CVD) incidents. Monitoring risk factors is critical to prevent the recurrence of CVD.Entities:
Keywords: CVD; ICF; ischemic stroke; risk factors; secondary prevention
Mesh:
Substances:
Year: 2022 PMID: 35329054 PMCID: PMC8948762 DOI: 10.3390/ijerph19063368
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Characteristics of the study groups.
| SG | CG |
| ||
|---|---|---|---|---|
| Sex | Males | 28 (50.9%) | 28 (50.9%) | 1.0 a |
| Females | 27 (49.1%) | 27 (49.1%) | ||
| Age (years) | Mean ± SD | 63.2 ± 8.8 | 65.9 ± 6.3 | 0.066 b |
| Median | 63.4 | 67 | ||
| Min–Max | 42.7–78.9 | 47.0–77.0 | ||
| BMI | Mean ± SD | 28.9 ± 4.6 | 28.6 ± 4.9 | 0.630 b |
| Median | 28.7 | 28 | ||
| Min–Max | 18.6–37.8 | 21.0–42.8 | ||
| Comorbidites | ||||
| Hypertension | 50 (90.9%) | 32 (58.2%) | <0.001 a | |
| Coronary heart disease | 16 (29.1%) | 6 (10.9%) | 0.017 a | |
| Chronic heart failure | 18 (32.7%) | 7 (12.7%) | <0.001 a | |
| Diabetes melitus type 2 | 24 (43.6) | 17 (30.9%) | 0.168 a | |
| Carotid artery disease | 30 (54.5%) | 3 (5.5) | <0.001 a | |
a chi2 test; b Mann-Whitney test; BMI—Body mass index CG—control group; n—size of the sample; SG—Stroke group; SD—standard devation.
Differences in the incidence of CVD risk factors depend on the history of non-ischemic stroke and gender.
| SG vs. CG | Females | Males | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SG | CG |
| SG | CG |
| SG | CG |
| ||
| b152 Emotional functions—Depression [ | 12 (21.8%) | 5 (9.3%) | 0.071 | 7 (25.0%) | 4 (14.3%) | 0.314 | 5 (18.5%) | 1 (3.8%) | 0.092 | |
| b134 Sleep functions—Insomia [ | 12 (21.8%) | 20 (36.4%) | 0.092 | 7 (25.0%) | 9 (32.1%) | 0.556 | 5 (18.5%) | 11 (40.7%) | 0.074 | |
| b4100 Heart rate [ | HR > 80/min, | 25 (46.3%) | 12 (21.8%) | 0.007 | 15 (53.6%) | 10 (35.7%) | 0.179 | 10 (38.5%) | 2 (7.4%) | 0.007 |
| b4101 Heart rhythm [ | Atrial fibrillation, | 15 (27.3%) | 5 (9.1%) | 0.013 | 6 (21.4%) | 4 (14.3%) | 0.485 | 9 (33.3%) | 1 (3.8%) | 0.005 |
| b4150 Functions of arteries [ | Stenosis 50–69%, | 15 (27.3%) | 1 (1.8%) | <0.001 | 8 (28.6%) | 1 (3.6%) | 0.011 | 7 (25.9%) | 0 (0.0%) | 0.005 |
| Stenosis > 70%, | 15 (27.3%) | 0 (0.0%) | <0.001 | 7 (25.0%) | 0 (0.0%) | 0.005 | 8 (29.6%) | 0 (0.0%) | 0.002 | |
| b4200 Increased blood pressure [ | >140/90 mmHg, | 50 (90.9%) | 32 (58.2%) | <0.001 | 25 (92.6%) | 16 (59.3%) | 0.004 | 25 (92.6%) | 16 (59.3%) | 0.004 |
| b4302 Metabolite-carrying functions of the blood [ | eGFR (mL/min/1.73 m2) < 15, | 6 (10.9%) | 5 (9.1%) | 0.753 | 3 (10.7%) | 4 (14.3%) | 0.686 | 3 (11.1%) | 1 (3.8%) | 0.299 |
| Bilirubin > 2x ULN, ALT/AST/ALP > 3x ULN, | 5 (9.1%) | 1 (1.8%) | 0.092 | 4 (14.3%) | 1 (3.6%) | 0.16 | 1 (3.8%) | 0 (0.0%) | 0.313 | |
| b4303 Functions related to the coagulation of blood [ | VKA, | 11 (20.0%) | 9 (16.4%) | 0.625 | 6 (21.4%) | 7 (25.0%) | 0.752 | 5 (18.5%) | 2 (7.4%) | 0.224 |
| NOAC, | 9 (16.4%) | 1 (1.8%) | 0.008 | 5 (17.9%) | 1 (3.6%) | 0.084 | 4 (14.8%) | 0 (0.0%) | 0.038 | |
| b5401 Carbohydrate metabolism [ | HbA1 >7%, | 23 (41.8%) | 14 (25.5%) | 0.07 | 9 (32.1%) | 5 (17.9%) | 0.217 | 14 (51.9%) | 9 (33.3%) | 0.169 |
| b7302 Lipid metabolism [ | LDL 55–70 mg/dL, | 6 (10.9%) | 8 (14.5%) | 0.571 | 3 (10.7%) | 5 (17.9%) | 0.442 | 3 (11.1%) | 3 (11.1%) | 1 |
| LDL 71–115 mg/dL, | 20 (36.4%) | 4 (7.3%) | <0.001 | 12 (42.9%) | 1 (3.6%) | <0.001 | 8 (29.6%) | 3 (11.1%) | 0.091 | |
| LDL > 116 mg/dL, | 25 (45.5%) | 0 (0.0%) | <0.001 | 12 (42.9%) | 0 (0.0%) | <0.001 | 13 (48.1%) | 0 (0.0%) | <0.001 | |
| e1100 Food [ | Alcohol consumption > 10 g (>1 unit), | 1 (1.8%) | 1 (1.8%) | 1 | 0 (0.0%) | 0 (0.0%) | 1 | 1 (3.8%) | 1 (3.8%) | 1 |
| e1101 Drugs [ | NSAIDs, | 46 (83.6%) | 35 (63.6%) | 0.017 | 21 (75.0%) | 19 (67.9%) | 0.554 | 25 (92.6%) | 16 (59.3%) | 0.004 |
| e1109 Products or substances for personal consumption, other specified [ | Smoking, | 19 (34.5%) | 5 (9.1%) | 0.001 | 8 (28.6%) | 2 (7.1%) | 0.036 | 11 (40.7%) | 3 (11.1%) | 0.013 |
Chi-squared test ALT—Alanine aminotransferase; AST—Aspartate aminotransferase; ALP—Alkaline phosphatase; CVD—Cardiovascular disease; eGFR—Estimated glomerular filtration rate; HbA1c—Glycated hemoglobin 1c; HR—Heart rate; LDL—Low-density lipoprotein cholesterol; NOAC—Non-vitamin K antagonist oral anticoagulants; NSAIDs—Nonsteroidal anti-inflammatory drugs; ULN—Upper limit of normal, VKA—Vitamin K antagonist.
Profile of CVD risk factors as per categories of the ICF classification.
| ICF Category | Complete | Severe | Modrate | Mild | No | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Body Functions | Scoring | Percentage Distribution of Occurrence of Qualifiers | ||||||||
| b152 Emotional functions [ | Depresion BDI | 26–63 | 20–25 | 10–12 | 0–9 | |||||
| SG | 21.80% | 78.20% | ||||||||
| CG | 9.30% | 90.70% | ||||||||
| SG Females | 25.00% | 75.00% | ||||||||
| CG Females | 14.30% | 85.70% | ||||||||
| SG Males | 18.50% | 81.50% | ||||||||
| CG Males | 3.80% | 96.20% | ||||||||
| b134 Sleep functions [ | Sleep time (h) | <6 and >9 | 6 to 9 | |||||||
| SG | 36.40% | 63.60% | ||||||||
| CG | 21.80% | 78.20% | ||||||||
| SG Females | 32.10% | 67.90% | ||||||||
| CG Females | 25.00% | 75.00% | ||||||||
| SG Males | 40.70% | 59.30% | ||||||||
| CG Males | 18.50% | 81.50% | ||||||||
| b4100 Heart rate [ | HR | >80/min | <80/min | |||||||
| SG | 46.30% | 53.70% | ||||||||
| CG | 21.80% | 78.20% | ||||||||
| SG Females | 53.60% | 46.40% | ||||||||
| CG Females | 35.70% | 64.30% | ||||||||
| SG Males | 38.50% | 61.50% | ||||||||
| CG Males | 7.40% | 92.60% | ||||||||
| b4101 Heart rhythm [ | Heart Rhythm | Atrial Fibrillation | Normal sinus rhythm | |||||||
| SG | 27.30% | 72.70% | ||||||||
| CG | 9.10% | 90.90% | ||||||||
| SG Females | 21.40% | 78.60% | ||||||||
| CG Females | 14.30% | 85.70% | ||||||||
| SG Males | 33.30% | 66.70% | ||||||||
| CG Males | 3.80% | 96.20% | ||||||||
| b4150 Functions of arteries [ | Stenosis (%) | >70 | 50–69 | <50 | ||||||
| SG | 27.30% | 27.30% | 45.40% | |||||||
| CG | 1.80% | 98.20% | ||||||||
| SG Females | 25.00% | 28.60% | 46.40% | |||||||
| CG Females | 3.60% | 96.40% | ||||||||
| SG Males | 29.60% | 25.90% | 44.50% | |||||||
| CG Males | 100.00% | |||||||||
| b4200 Increased blood pressure [ | BP (mmHg) | >180/110 | >160/90 | >140/90 | >130/80 | <130/80 | ||||
| SG | 4.50% | 15.00% | 25.50% | 25.00% | 30.50% | |||||
| CG | 18.50% | 34.20% | 47.30% | |||||||
| SG Females | 4.50% | 35.50% | 45.50% | 4.50% | 2.50% | |||||
| CG Females | 20.50% | 39.30% | 40.70% | |||||||
| SG Males | 3.80% | 30.50% | 25.50% | 25.00% | 7.80% | |||||
| CG Males | 30.00% | 29.30% | 40.70% | |||||||
| b4302 Metabolite-carrying functions of the blood [ | eGFR (mL/min/1.73 m2) | <15 | 15–29 | 30–59 | 60–89 | >90 | ||||
| SG | 5.00% | 5.90% | 89.10% | |||||||
| CG | 4.10% | 5.00% | 91.00% | |||||||
| SG Females | 5.00% | 5.70% | 89.30% | |||||||
| CG Females | 4.30% | 10.00% | 86.00% | |||||||
| SG Males | 5.00% | 6.10% | 88.90% | |||||||
| CG Males | 3.80% | 96.20% | ||||||||
| Bilirubin (ULN) | >2× | <2× | ||||||||
| ALT/AST/Alkaline phosphatase (ULN) | >3× | <3× | ||||||||
| SG | 9.10% | 90.90% | ||||||||
| CG | 1.80% | 98.20% | ||||||||
| SG Females | 14.30% | 85.70% | ||||||||
| CG Females | 3.60% | 96.40% | ||||||||
| SG Males | 3.80% | 96.00% | ||||||||
| CG Males | 100.00% | |||||||||
| b4303 Functions related to the coagulation of blood [ | VKA | YES | NO | |||||||
| SG | 20.00% | 80.00% | ||||||||
| CG | 16.40% | 83.60% | ||||||||
| SG Females | 21.40% | 78.60% | ||||||||
| CG Females | 25.00% | 75.00% | ||||||||
| SG Males | 18.50% | 81.50% | ||||||||
| CG Males | 7.40% | 92.60% | ||||||||
| NOAC | YES | NO | ||||||||
| SG | 16.40% | 83.60% | ||||||||
| CG | 1.80% | 98.20% | ||||||||
| SG Females | 17.90% | 82.10% | ||||||||
| CG Females | 3.60% | 96.40% | ||||||||
| SG Males | 14.80% | 85.20% | ||||||||
| CG Males | 100.00% | |||||||||
| b5401 Carbohydrate metabolism [ | HbA1 (%) | >7 | <7 | |||||||
| SG | 41.80% | 58.20% | ||||||||
| CG | 25.50% | 74.50% | ||||||||
| SG Females | 32.10% | 67.90% | ||||||||
| CG Females | 17.90% | 82.10% | ||||||||
| SG Males | 51.90% | 48.10% | ||||||||
| CG Males | 33.10% | 66.70% | ||||||||
| b7302 Lipid metabolism [ | LDL-C (mg/dL) | >116 | 115–71 | 70–55 | <55 | |||||
| SG | 45.50% | 36.40% | 10.90% | 7.20% | ||||||
| CG | 7.30% | 14.50% | 78.20% | |||||||
| SG Females | 42.90% | 42.90% | 10.70% | 3.50% | ||||||
| CG Females | 3.60% | 17.90% | 78.50% | |||||||
| SG Males | 48.10% | 29.60% | 11.10% | 11.20% | ||||||
| CG Males | 11.10% | 11.10% | 77.80% | |||||||
|
| ||||||||||
| e1100 Food [ | Alcohol consumption (g) | >10 | <10 | |||||||
| SG | 1.80% | 98.20% | ||||||||
| CG | 1.80% | 98.20% | ||||||||
| SG Females | 100.00% | |||||||||
| CG Females | 100.00% | |||||||||
| SG Males | 3.80% | 96.20% | ||||||||
| CG Males | 3.80% | 96.20% | ||||||||
| e1101 Drugs [ | NSAIDs | YES | NO | |||||||
| SG | 83.60% | 16.40% | ||||||||
| CG | 63.60% | 36.40% | ||||||||
| SG Females | 75.00% | 25.00% | ||||||||
| CG Females | 67.90% | 32.10% | ||||||||
| SG Males | 92.60% | 7.40% | ||||||||
| CG Males | 59.30% | 40.70% | ||||||||
| e1109 Products or substances for personal consumption, other specified [ | Smoking | YES | NO | |||||||
| SG | 34.50% | 65.50% | ||||||||
| CG | 9.10% | 90.90% | ||||||||
| SG Females | 28.60% | 71.40% | ||||||||
| CG Females | 7.10% | 92.90% | ||||||||
| SG Males | 40.70% | 59.30% | ||||||||
| CG Males | 11.10% | 88.90% | ||||||||
ALT—Alanine aminotransferase; AST—Aspartate aminotransferase; ALP—Alkaline phosphatase; BP—Blood pressure; CVD—Cardiovascular disease; eGFR—Estimated glomerular filtration rate; ICH—intracerebral hemorrhage; ICF—International Classification of Functioning, Disability and Health; IS—ischemic stroke; HbA1c—Glycated hemoglobin 1c; HR—Heart rate; LDL-C—Low-density lipoprotein cholesterol; n—size of the sample; NOAC—Nonvitamin K antagonist oral anticoagulants; NSAIDs—Nonsteroidal anti-inflammatory drugs; ULN—Upper limit of normal; VKA—Vitamin K antagonist.
Differences in the incidence of the total value of CVD risk factors.
| CG vs. SG | Females | Males | |||||||
|---|---|---|---|---|---|---|---|---|---|
| SG | CG |
| SG | CG |
| SG | CG |
| |
| Mean ± SD | 5.5 ± 1.9 | 2.8 ± 1.5 | <0.001 | 5.4 ± 1.7 | 3.2 ± 1.5 | <0.001 | 5.6 ± 2.2 | 2.4 ± 1.4 | <0.001 |
| Median | 5 | 3 | 5 | 3 | 6 | 2 | |||
| Min–Max | 2–10 | 0–6 | 3–9 | 1–6 | 2–10 | 0–5 | |||
CG—control group; CVD—cardiovascular disease; SD—standard deviation; SG—post-ischemic stroke group.
Figure 1Distribution of the total of CVD risk factors. Note: CVD—cardiovascular disease; CG—control group; SG—post-ischemic stroke group.